On April 2, 2020, the Patented Medicine Prices Review Board (PMPRB) published a message from the Chairperson regarding the results of its consultation on the draft Guidelines operationalizing the amended Patented Medicines Regulations (reported here). The PMPRB will be making “significant changes” to the draft Guidelines in response to the feedback it received during the consultation and intends to publish a revised draft for comment this spring. The Chairperson further noted that, in view of COVID-19, the PMPRB would reassess the intended next steps closer to the date of their publication.
On April 15, 2020, the PMPRB published six additional stakeholder submissions that had been inadvertently omitted from the set of submissions previously published on its consultation portal (reported here).
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.